Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?
Topical ophthalmic instillation is an appealing strategy to deliver drugs to the back of the eye to treat retinal diseases such as neovascular age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and glaucomatous optic neuropathy. It has several advantages such as being no...
Saved in:
| Published in | Frontiers in Drug Delivery Vol. 2 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
08.09.2022
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | Topical ophthalmic instillation is an appealing strategy to deliver drugs to the back of the eye to treat retinal diseases such as neovascular age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and glaucomatous optic neuropathy. It has several advantages such as being non-invasive and user-friendly, e.g., allowing self-administration. However, the main obstacle has been how to achieve therapeutic drug concentrations in the retina due to the eye’s protective mechanisms, flows, and barriers. Less than 4% of the instilled drug dose enters the anterior chamber, and much less is expected to reach the posterior segment. It is crucial to understand a drug’s topical pharmacokinetics in humans and how one can extrapolate data from rabbits to humans. In this review, the available data on the retina and vitreous drug concentrations from pharmacokinetics studies conducted in human patients and rabbits have been compiled, together with the critical physiological factors to be considered for this route of administration. Improvements in the design of preclinical studies are suggested to increase their translatability to the treatment of human patients. Finally, the current status of clinical trials with topical ophthalmic formulations intended to treat the back of the eye is depicted. At present, no topical ophthalmic formulations to treat neovascular age-related macular degeneration or other retinal neurodegenerative illnesses have reached the market. |
|---|---|
| AbstractList | Topical ophthalmic instillation is an appealing strategy to deliver drugs to the back of the eye to treat retinal diseases such as neovascular age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and glaucomatous optic neuropathy. It has several advantages such as being non-invasive and user-friendly, e.g., allowing self-administration. However, the main obstacle has been how to achieve therapeutic drug concentrations in the retina due to the eye’s protective mechanisms, flows, and barriers. Less than 4% of the instilled drug dose enters the anterior chamber, and much less is expected to reach the posterior segment. It is crucial to understand a drug’s topical pharmacokinetics in humans and how one can extrapolate data from rabbits to humans. In this review, the available data on the retina and vitreous drug concentrations from pharmacokinetics studies conducted in human patients and rabbits have been compiled, together with the critical physiological factors to be considered for this route of administration. Improvements in the design of preclinical studies are suggested to increase their translatability to the treatment of human patients. Finally, the current status of clinical trials with topical ophthalmic formulations intended to treat the back of the eye is depicted. At present, no topical ophthalmic formulations to treat neovascular age-related macular degeneration or other retinal neurodegenerative illnesses have reached the market. |
| Author | del Amo, Eva M. |
| Author_xml | – sequence: 1 givenname: Eva M. surname: del Amo fullname: del Amo, Eva M. |
| BookMark | eNp9kMtOwzAQRS1UJErpB7DzD6Q4sRPbbBCqeEmV2JR1NPGDGNK4sl2gf0-askAs0CzmLuaMZs45mvS-Nwhd5mRBqZBXVmvzsShIUSxkyTjPT9C0qDjLiCjJ5Fc-Q_MY3wghheCM8GqKPtd-6xR02G_b1EK3cQqD3rjexRQgOd9f4yX0GLAOu1fs-phc1xmNfZ88Tq3BXu06CDjuggVlsPkyIeGBMNYaNaQ0TjWg3rG3YzZ7c3OBTi100cx_-gy93N-tl4_Z6vnhaXm7yhQtq5RpyrTkXALhIAG01nlDm4YPt5eWk0JqIpikrMwrCmIoxqXQRGljWU6UoDPEj3tV8DEGY2vl0vjX8J7r6pzUB4X1qLA-KKyPCgcy_0Nug9tA2P_DfANTTXjR |
| CitedBy_id | crossref_primary_10_3390_toxics12070513 crossref_primary_10_1016_j_jddst_2023_104281 crossref_primary_10_1016_j_pharma_2024_08_003 crossref_primary_10_1016_j_jphs_2022_10_005 crossref_primary_10_7124_bc_000AA1 crossref_primary_10_1016_j_ijpharm_2024_124018 crossref_primary_10_3390_ijms24032361 crossref_primary_10_1016_j_bbrc_2024_150212 crossref_primary_10_1016_j_ejpb_2024_114260 crossref_primary_10_1002_cssc_202301220 crossref_primary_10_1167_iovs_65_11_28 crossref_primary_10_1167_iovs_65_12_14 crossref_primary_10_1097_CRD_0000000000000801 crossref_primary_10_1016_j_cis_2024_103200 crossref_primary_10_1021_acs_molpharmaceut_4c00725 |
| Cites_doi | 10.1089/jop.2018.0138 10.1016/j.jddst.2018.04.007 10.1016/j.ijpharm.2021.121361 10.1111/j.1755-3768.1987.tb08493.x 10.1016/0039-6257(93)90141-s 10.1016/j.ejps.2020.105553 10.2174/1872211308666140130093301 10.3390/pharmaceutics14010134 10.1016/j.ejps.2012.05.007 10.1007/978-3-540-69469-4_2 10.1089/jop.1997.13.41 10.1007/978-3-030-76367-1_21 10.1016/j.ejpb.2021.06.003 10.4155/cli.15.5 10.1016/j.ejpb.2022.01.005 10.1159/000266930 10.1016/j.ejps.2017.07.027 10.1016/j.exer.2015.05.003 10.3109/02713683.2015.1050738 10.1007/978-3-030-27492-4_6 10.1016/j.addr.2017.12.008 10.1007/978-3-030-76367-1_1 10.1002/prp2.545 10.1007/s13346-015-0275-6 10.1167/iovs.16-19952 10.1016/j.survophthal.2021.12.003 10.1016/B978-0-12-374203-2.00169-X 10.1016/j.ejps.2018.07.034 10.1002/jps.2600760802 10.1016/0378-5173(87)90092-5 10.1021/acs.molpharmaceut.8b00038 10.1177/000331979404500603 10.1097/IAE.0b013e3181b094e6 10.1021/js9802594 10.1016/j.jconrel.2004.10.004 10.1586/eop.10.55 10.1016/j.ejpb.2015.01.003 10.1124/dmd.30.4.421 10.1089/jop.1995.11.489 10.1167/tvst.10.14.23 10.1016/0014-4835(78)90086-6 10.1038/s41573-021-00284-4 10.1016/j.preteyeres.2016.12.001 10.1002/jps.2600620712 10.1007/978-3-642-69222-2_2 10.3109/02713688809031801 10.1016/s0002-9394(14)78371-0 10.1111/bcp.13794 10.1021/acs.molpharmaceut.9b01024 10.1016/s0002-9394(14)70490-8 10.1016/j.ejps.2018.03.034 10.1016/j.ophtha.2014.05.013 10.1124/jpet.118.248427 10.1097/APO.0000000000000291 10.1016/j.ijpharm.2021.120332 10.1021/acs.molpharmaceut.0c01154 10.1021/acs.jmedchem.7b01731 10.1016/j.addr.2018.03.013 10.1016/0002-9394(86)90771-3 10.1016/j.ijpharm.2022.121515 10.1016/S2214-109X(13)70145-1 10.1136/bmjophth-2019-000398 10.1016/0014-4835(73)90185-1 10.1016/j.exer.2015.10.009 10.1007/s11095-010-0132-8 10.1016/0169-409X(95)00010-5 10.1152/ajpheart.00643.2003 10.1016/s0161-6420(00)00654-0 10.1016/s0002-9394(14)73646-3 10.1016/0378-5173(90)90215-p 10.1016/j.xphs.2020.09.051 10.1167/iovs.05-0945 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION |
| DOI | 10.3389/fddev.2022.954771 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2674-0850 |
| ExternalDocumentID | 10_3389_fddev_2022_954771 |
| GroupedDBID | 9T4 AAFWJ AAYXX AFPKN ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ M~E |
| ID | FETCH-LOGICAL-c356t-d34d9779a07a9aaddd1b3bb70765f7029d0849345163a8a8a4798d0cdef410c83 |
| ISSN | 2674-0850 |
| IngestDate | Thu Apr 24 22:56:57 EDT 2025 Tue Jul 01 02:51:04 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c356t-d34d9779a07a9aaddd1b3bb70765f7029d0849345163a8a8a4798d0cdef410c83 |
| OpenAccessLink | https://doi.org/10.3389/fddev.2022.954771 |
| ParticipantIDs | crossref_citationtrail_10_3389_fddev_2022_954771 crossref_primary_10_3389_fddev_2022_954771 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-08 |
| PublicationDateYYYYMMDD | 2022-09-08 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in Drug Delivery |
| PublicationYear | 2022 |
| References | B64 Heikkinen (B37) 2018; 123 Prausnitz (B67) 1998; 87 Slack (B84) 2022; 21 Wong (B91) 2014; 2 Mishima (B58) 1966; 5 Urtti (B87) 1990; 61 Rimpelä (B71) 2018; 15 Acheampong (B1) 1995; 11 del Amo (B26) 2022; 2022 Huupponen (B44) 2009; 65 del Amo (B25) 2022; 613 Sebag (B79) 1994; 45 Ahmed (B7) 1987; 38 Hopkins (B39) Schoenwald (B77) 1997; 13 Adams (B4) 2018; 61 Tham (B86) 2014; 121 Varner (B89) 2015; 5 Alm (B10) 1973; 15 Holló (B38) 2006; 47 Sigurdsson (B83) 2005; 102 Balla (B16) 2022; 172 Loch (B54) 2012; 47 Yu (B92) 2004; 286 Naageshwaran (B59) 2022; 615 B78 Boddu (B18) 2014; 8 Acheampong (B2) 2002; 30 Lederer (B53) 1986; 101 Hayreh (B35) 2006 Petternel (B66) 2004; 45 Rimpelä (B70) 2018; 126 Rush (B73) 2016; 57 Barany (B17) 1949; 32 Hopkins (B40) Kent (B48) 2001; 108 Sherman (B81) 1978; 27 Hammid (B34) 2021; 18 Kompella (B51) 2019; 35 Neervannan (B61) 2021 Ramsay (B68) 2018; 119 Chiou (B22) 1989; 21 Ambati (B11) 2000; 41 Fayyaz (B32) 2021; 166 del Amo (B27) 2017; 57 Joussen (B47) 2019; 85 Shikamura (B82) 2016; 41 Nilsson (B62) 2012 Huang (B42) 1989; 30 Shalaby (B80) 2022; 67 Chrai (B23) 1973; 62 Lau (B52) 2018; 126 O’Rourke (B63) 2021 Anand-Apte (B12) 2010 Hämäläinen (B33) 1997; 38 Maurice (B57) 1984 Ahmed (B8) 1985; 26 Kidron (B49) 2010; 27 Johannsdottir (B46) 2018; 45 Mandell (B56) 1993; 115 Naageshwaran (B60) 2021; 110 Askew (B14) 2018; 366 del Amo (B29) 2015; 95 B94 B95 Chastain (B21) 2016; 145 Alghamdi (B9) 2020 del Amo (B28) 2015; 137 Brubaker (B20) 1982; 80 Horita (B41) 2019; 7 Sahlin (B74) 1996; 122 Klar (B50) 2015; 56 Schauersberger (B76) 2002; 43 B15 Chua (B24) 2010; 5 Heier (B36) 2009; 29 Huang (B43) 2021; 10 Pelkonen (B65) 2017; 109 Watsky (B90) 1988; 7 Acheampong (B3) 1995; 23 Araie (B13) 1982; 26 Urtti (B88) 1993; 37 Khanna (B93) 2019; 4 Fayyaz (B31); 155 Boettger (B19) 2015; 56 Fayyaz (B30); 17 Agarwal (B5) 2016; 6 Järvinen (B45) 1995; 16 Löscher (B55) 2022; 14 Rodrigues (B72) 2018 Ahmed (B6) 1987; 76 Remington (B69) 2021 Samanta (B75) 2020; 9 Sripetch (B85) 2021; 597 |
| References_xml | – volume: 35 start-page: 457 year: 2019 ident: B51 article-title: ISOPT clinical hot topic panel discussion on ocular drug delivery publication-title: J. Ocular Pharmacol. Ther. doi: 10.1089/jop.2018.0138 – volume: 45 start-page: 449 year: 2018 ident: B46 article-title: Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits publication-title: J. Drug Deliv. Sci. Technol. doi: 10.1016/j.jddst.2018.04.007 – volume: 56 start-page: 2294 year: 2015 ident: B19 article-title: Topically administered regorafenib eye drops inhibit grade IV lesions in the non-human primate laser CNV model publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 5 start-page: 264 year: 1966 ident: B58 article-title: Determination of tear volume and tear flow publication-title: Investig. Ophthalmol. – start-page: 288 volume-title: Clinical anatomy and physiology of the visual system year: 2021 ident: B69 article-title: Clinical anatomy and physiology of the visual system – start-page: 67 volume-title: Ophthalmic drugs: Diagnostic and therapeutic uses ident: B40 article-title: Ophthalmic dosage forms – volume: 45 start-page: 4930 year: 2004 ident: B66 article-title: Fosfomycin in human vitreous: –in–vitro investigation of the protein binding of fosfomycin in human vitreous –fosfomycin levels in the vitreous cavity after intravenous administration publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 23 start-page: 708 year: 1995 ident: B3 article-title: Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits publication-title: Drug Metab. Dispos. – volume: 613 start-page: 121361 year: 2022 ident: B25 article-title: Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2021.121361 – volume: 65 start-page: 63 year: 2009 ident: B44 article-title: The pharmacokinetics of ocularly applied timolol in rabbits publication-title: Acta Ophthalmol. doi: 10.1111/j.1755-3768.1987.tb08493.x – volume: 37 start-page: 435 year: 1993 ident: B88 article-title: Minimizing systemic absorption of topically administered ophthalmic drugs publication-title: Surv. Ophthalmol. doi: 10.1016/0039-6257(93)90141-s – ident: B64 – volume: 155 start-page: 105553 ident: B31 article-title: Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2020.105553 – volume: 8 start-page: 27 year: 2014 ident: B18 article-title: Drug delivery to the back of the eye following topical administration: An update on research and patenting activity publication-title: Recent Pat. Drug Deliv. Formul. doi: 10.2174/1872211308666140130093301 – volume: 30 start-page: 684 year: 1989 ident: B42 article-title: Paracellular permeability of corneal and conjunctival epithelia publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 14 year: 2022 ident: B55 article-title: Topical drug delivery to the posterior segment of the eye publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14010134 – volume: 47 start-page: 131 year: 2012 ident: B54 article-title: Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2012.05.007 – volume: 26 start-page: 248 year: 1982 ident: B13 article-title: Beta-adrenergic blockers: Ocular penetration and binding to the uveal pigment publication-title: Jpn. J. Ophthalmol. – start-page: 25 volume-title: Ocular blood flow year: 2012 ident: B62 article-title: Determination of ocular blood flows with the microsphere method doi: 10.1007/978-3-540-69469-4_2 – volume: 13 start-page: 41 year: 1997 ident: B77 article-title: Penetration into the anterior chamber via the conjunctival/scleral pathway publication-title: J. Ocul. Pharmacol. Ther. doi: 10.1089/jop.1997.13.41 – volume-title: Controlled release society focus group – ocular webinar, feb 2021 year: 2021 ident: B63 article-title: The development and commercialization of sustained-release ocular drug delivery delivery technologies doi: 10.1007/978-3-030-76367-1_21 – volume: 166 start-page: 155 year: 2021 ident: B32 article-title: Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2021.06.003 – volume: 5 start-page: 457 year: 2015 ident: B89 article-title: Ophthalmic pharmaceutical clinical trials: Design considerations publication-title: Clin. Investig. (Lond). doi: 10.4155/cli.15.5 – volume: 56 start-page: 246 year: 2015 ident: B50 article-title: Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 172 start-page: 53 year: 2022 ident: B16 article-title: Understanding dexamethasone kinetics in the rabbit tear fluid: Drug release and clearance from solution, suspension and hydrogel formulations publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2022.01.005 – start-page: 257 volume-title: Ophthalmic drugs:diagnostic and therapeutic uses ident: B39 article-title: Indications and contraindications for ophthalmic drugs – volume: 21 start-page: 406 year: 1989 ident: B22 article-title: Microvascular access to the uveal tract in the rabbit eye for ocular pharmacologic studies. publication-title: Ophthalmic Res. doi: 10.1159/000266930 – volume: 109 start-page: 162 year: 2017 ident: B65 article-title: Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2017.07.027 – volume: 137 start-page: 111 year: 2015 ident: B28 article-title: Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data publication-title: Exp. Eye Res. doi: 10.1016/j.exer.2015.05.003 – volume: 41 start-page: 653 year: 2016 ident: B82 article-title: Hydrogel ring for topical drug delivery to the ocular posterior segment publication-title: Curr. Eye Res. doi: 10.3109/02713683.2015.1050738 – start-page: 17 volume-title: Extemporaneous ophthalmic preparations year: 2020 ident: B9 article-title: Topical ophthalmic drug forms doi: 10.1007/978-3-030-27492-4_6 – volume: 126 start-page: 23 year: 2018 ident: B70 article-title: Implications of melanin binding in ocular drug delivery publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2017.12.008 – volume: 43 start-page: 1853 year: 2002 ident: B76 article-title: -vitro investigation of the protein binding of different antibiotics in the human vitreous publication-title: Investig. Ophthalmol. Vis. Sci. – start-page: 3 volume-title: Ophthalmic product development: From bench to bedside year: 2021 ident: B61 article-title: Introduction and history of ophthalmic product development doi: 10.1007/978-3-030-76367-1_1 – volume: 7 start-page: e00545 year: 2019 ident: B41 article-title: Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys publication-title: Pharmacol. Res. Perspect. doi: 10.1002/prp2.545 – volume: 6 start-page: 634 year: 2016 ident: B5 article-title: In vitro and ex vivo corneal penetration and absorption models publication-title: Drug Deliv. Transl. Res. doi: 10.1007/s13346-015-0275-6 – volume: 57 start-page: 5864 year: 2016 ident: B73 article-title: Administration of menadione, vitamin K3, ameliorates off-target effects on corneal epithelial wound healing due to receptor tyrosine kinase inhibition publication-title: Investig. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.16-19952 – volume: 67 start-page: 1062 year: 2022 ident: B80 article-title: A review of potential novel glaucoma therapeutic options independent of intraocular pressure publication-title: Surv. Ophthalmol. doi: 10.1016/j.survophthal.2021.12.003 – start-page: 9 volume-title: Encyclopedia of the eye year: 2010 ident: B12 article-title: Developmental anatomy of the retinal and choroidal vasculature doi: 10.1016/B978-0-12-374203-2.00169-X – volume: 123 start-page: 106 year: 2018 ident: B37 article-title: Esterase activity in porcine and albino rabbit ocular tissues publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2018.07.034 – volume: 76 start-page: 583 year: 1987 ident: B6 article-title: Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600760802 – volume: 38 start-page: 9 year: 1987 ident: B7 article-title: Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption publication-title: Int. J. Pharm. X. doi: 10.1016/0378-5173(87)90092-5 – volume: 15 start-page: 2174 year: 2018 ident: B71 article-title: Binding of small molecule drugs to porcine vitreous humor publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.8b00038 – volume: 45 start-page: 429 year: 1994 ident: B79 article-title: Effects of pentoxifylline on choroidal blood flow in nonproliferative diabetic retinopathy publication-title: Angiology doi: 10.1177/000331979404500603 – start-page: 1130 volume-title: Eye year: 2006 ident: B35 article-title: Orbital vascular anatomy – volume: 2022 start-page: 59 year: 2022 ident: B26 article-title: Pharmacokinetic models: Indispensable tools for ophthalmic drug development publication-title: ONdrugDelivery – volume: 26 start-page: 584 year: 1985 ident: B8 article-title: Importance of the noncorneal absorption route in topical ophthalmic drug delivery publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 29 start-page: 1310 year: 2009 ident: B36 article-title: Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. publication-title: Retina doi: 10.1097/IAE.0b013e3181b094e6 – volume: 87 start-page: 1479 year: 1998 ident: B67 article-title: Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. publication-title: J. Pharm. Sci. doi: 10.1021/js9802594 – volume: 102 start-page: 255 year: 2005 ident: B83 article-title: Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration publication-title: J. Control. Release doi: 10.1016/j.jconrel.2004.10.004 – volume: 5 start-page: 627 year: 2010 ident: B24 article-title: Neuroprotective agents in glaucoma therapy: Recent developments and future directions publication-title: Expert Rev. Ophthalmol. doi: 10.1586/eop.10.55 – volume: 95 start-page: 215 year: 2015 ident: B29 article-title: Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2015.01.003 – volume: 30 start-page: 421 year: 2002 ident: B2 article-title: Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.30.4.421 – volume: 11 start-page: 489 year: 1995 ident: B1 article-title: Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits publication-title: J. Ocul. Pharmacol. Ther. doi: 10.1089/jop.1995.11.489 – volume: 10 start-page: 23 year: 2021 ident: B43 article-title: A novel eye drop formulation for potential treatment of neovascular age-related macular degeneration publication-title: Transl. Vis. Sci. Technol. doi: 10.1167/tvst.10.14.23 – volume: 38 start-page: 627 year: 1997 ident: B33 article-title: Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 27 start-page: 159 year: 1978 ident: B81 article-title: The fate of anterior chamber flurescein in the monkey eye. 1. The anterior chamber outflow pathways. publication-title: Exp. Eye Res. doi: 10.1016/0014-4835(78)90086-6 – volume: 21 start-page: 60 year: 2022 ident: B84 article-title: Emerging therapeutic opportunities for integrin inhibitors publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-021-00284-4 – start-page: 245 volume-title: Pharm. Res. year: 2018 ident: B72 article-title: Topical drug delivery to the posterior segment of the eye: Addressing the challenge of preclinical to clinical translation – volume: 57 start-page: 134 year: 2017 ident: B27 article-title: Pharmacokinetic aspects of retinal drug delivery publication-title: Prog. Retin. Eye Res. doi: 10.1016/j.preteyeres.2016.12.001 – ident: B94 – volume: 62 start-page: 1112 year: 1973 ident: B23 article-title: Lacrimal and instilled fluid dynamics in rabbit eyes publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600620712 – start-page: 19 volume-title: Pharmacology of the eye year: 1984 ident: B57 article-title: Ocular pharmacokinetics doi: 10.1007/978-3-642-69222-2_2 – volume: 7 start-page: 483 year: 1988 ident: B90 article-title: Comparison of conjunctival and corneal surface areas in rabbit and human publication-title: Curr. Eye Res. doi: 10.3109/02713688809031801 – volume: 32 start-page: 177 year: 1949 ident: B17 article-title: The rate of flow of aqueous humor* publication-title: Am. J. Ophthalmol. doi: 10.1016/s0002-9394(14)78371-0 – volume: 85 start-page: 347 year: 2019 ident: B47 article-title: The developing regorafenib eye drops for neovascular age-related macular degeneration (DREAM) study: An open-label phase II trial publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.13794 – volume: 17 start-page: 588 ident: B30 article-title: Ocular intracameral pharmacokinetics for a cocktail of timolol, betaxolol, and atenolol in rabbits publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.9b01024 – volume: 122 start-page: 701 year: 1996 ident: B74 article-title: Evaluation of the lacrimal drainage function by the drop test publication-title: Am. J. Ophthalmol. doi: 10.1016/s0002-9394(14)70490-8 – volume: 119 start-page: 83 year: 2018 ident: B68 article-title: Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2018.03.034 – volume: 121 start-page: 2081 year: 2014 ident: B86 article-title: Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.05.013 – volume: 366 start-page: 244 year: 2018 ident: B14 article-title: Ocular distribution and pharmacodynamics of SF0166, a topically administered αvβ3 integrin antagonist, for the treatment of retinal diseases. publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.118.248427 – volume: 9 start-page: 250 year: 2020 ident: B75 article-title: Emerging therapies in neovascular age-related macular degeneration in 2020 publication-title: Asia Pac J. Ophthalmol. (Phila) doi: 10.1097/APO.0000000000000291 – volume: 597 start-page: 120332 year: 2021 ident: B85 article-title: Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2021.120332 – volume: 18 start-page: 1305 year: 2021 ident: B34 article-title: Carboxylesterase activities and protein expression in rabbit and pig ocular tissues publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.0c01154 – volume: 61 start-page: 1622 year: 2018 ident: B4 article-title: The discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (acrizanib), a VEGFR-2 inhibitor specifically designed for topical ocular delivery, as a therapy for neovascular age-related macular degeneration publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.7b01731 – ident: B95 – volume: 126 start-page: 145 year: 2018 ident: B52 article-title: Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: Current status and challenges publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2018.03.013 – volume: 101 start-page: 691 year: 1986 ident: B53 article-title: Drop size of commercial glaucoma medications publication-title: Am. J. Ophthalmol. doi: 10.1016/0002-9394(86)90771-3 – volume: 615 start-page: 121515 year: 2022 ident: B59 article-title: Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2022.121515 – volume: 2 start-page: e106 year: 2014 ident: B91 article-title: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis publication-title: Lancet. Glob. Health doi: 10.1016/S2214-109X(13)70145-1 – volume: 41 start-page: 1181 year: 2000 ident: B11 article-title: Diffusion of high molecular weight compounds through sclera publication-title: Investig. Ophthalmol. Vis. Sci. – volume: 80 start-page: 391 year: 1982 ident: B20 article-title: The flow of aqueous humor in the human eye publication-title: Trans. Am. Ophthalmol. Soc. – volume: 4 year: 2019 ident: B93 article-title: Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review publication-title: BMJ Open Ophthalmol. doi: 10.1136/bmjophth-2019-000398 – volume: 15 start-page: 15 year: 1973 ident: B10 article-title: Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macaca irus): A study with radioactively labelled microspheres including flow determinations in brain and some other tissues publication-title: Exp. Eye Res. doi: 10.1016/0014-4835(73)90185-1 – volume: 145 start-page: 58 year: 2016 ident: B21 article-title: Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye publication-title: Exp. Eye Res. doi: 10.1016/j.exer.2015.10.009 – volume: 27 start-page: 1398 year: 2010 ident: B49 article-title: Prediction of the corneal permeability of drug-like compounds publication-title: Pharm. Res. doi: 10.1007/s11095-010-0132-8 – volume: 16 start-page: 3 year: 1995 ident: B45 article-title: Ocular absorption following topical delivery publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/0169-409X(95)00010-5 – volume: 286 start-page: H419 year: 2004 ident: B92 article-title: Low oxygen consumption in the inner retina of the visual streak of the rabbit publication-title: Am. J. Physiol. Heart Circ. Physiol. doi: 10.1152/ajpheart.00643.2003 – ident: B15 – volume: 108 start-page: 784 year: 2001 ident: B48 article-title: Vitreous concentration of topically applied brimonidine tartrate 0.2% publication-title: Ophthalmology doi: 10.1016/s0161-6420(00)00654-0 – ident: B78 – volume: 115 start-page: 770 year: 1993 ident: B56 article-title: Effects of inflammation and surgery on amikacin levels in the vitreous cavity publication-title: Am. J. Ophthalmol. doi: 10.1016/s0002-9394(14)73646-3 – volume: 61 start-page: 241 year: 1990 ident: B87 article-title: Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits publication-title: Int. J. Pharm. X. doi: 10.1016/0378-5173(90)90215-p – volume: 110 start-page: 529 year: 2021 ident: B60 article-title: Comprehensive ocular and systemic pharmacokinetics of brinzolamide in rabbits after intracameral, topical, and intravenous administration publication-title: J. Pharm. Sci. doi: 10.1016/j.xphs.2020.09.051 – volume: 47 start-page: 235 year: 2006 ident: B38 article-title: Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration publication-title: Investig. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.05-0945 |
| SSID | ssj0002874076 |
| Score | 2.3090765 |
| SecondaryResourceType | review_article |
| Snippet | Topical ophthalmic instillation is an appealing strategy to deliver drugs to the back of the eye to treat retinal diseases such as neovascular age-related... |
| SourceID | crossref |
| SourceType | Enrichment Source Index Database |
| Title | Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye? |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZ97KXsU_WfZR7GH1Y6kyJFdvayzbalTLI6EMKfTOSJVOoF4fUacke9rfvTnJsp0thHQFjFPlsdD9Ld_Ld7xh7zw0XOVc60FKEgTC5DmQcykCJYZKZfCisS4-e_IhOzsT38_F5r_elm11S6UH2a2teyf9oFdtQr5Qlew_NNkKxAc9Rv3hEDePx33Rczt0Yl_OL6kIVFOauNshwyd8_xDdY9c1iSbkr-EIXBdqYxFrgbM7Sx6FeLRe5wlecKjBRzHkd51GnOva1yi7X0QR2ZW9FAx4TCQKV1KbNkyO60ZEtKN6j2a43FoHw0-3Kounenwy6mw3op9Knk878OIpiERDLnV8-trTVk-po2_SM7jCxm-Y4pV4PSPxAjkXsS7BsUmHfWqKawEF0WUhI6kSkJCL1Ih6whyN0FGimm_xud9mIzZ_7CoPrp_SftknKx78epGOcdKyM6RP2uHYP4KvX9VPWs7NnbP_U84uvDmDapstdHcA-nLbM46vn7KYGBLSAgE1AfAKEAyggOEADByA4ACoXPByghgM4OABe4eEAqnK9CA5Q5u4c4fD5BTs7_jY9PAnqyhpBFo6jKjChMGj4S8VjJRUucWaoQ61jHKpxHvORNDwRMqQizqFK8CdimRieGZuLIc-S8CXbmZUz-4oBChryKME_okwQn5w2iTJSZui4W7TWdxlfD2ma1bTzVP2kSO_U5S770Fwy95wrd3d-fZ_Ob9ijFtVv2U61WNp3aFRWes9txuw59PwBozJ47w |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Topical+ophthalmic+administration%3A+Can+a+drug+instilled+onto+the+ocular+surface+exert+an+effect+at+the+back+of+the+eye%3F&rft.jtitle=Frontiers+in+Drug+Delivery&rft.au=del+Amo%2C+Eva+M.&rft.date=2022-09-08&rft.issn=2674-0850&rft.eissn=2674-0850&rft.volume=2&rft_id=info:doi/10.3389%2Ffddev.2022.954771&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fddev_2022_954771 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2674-0850&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2674-0850&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2674-0850&client=summon |